| Literature DB >> 21854567 |
Jennie Johnstone1, Steven E Hanna, Lindsay E Nicolle, Michael A Drebot, Binod Neupane, James B Mahony, Mark B Loeb.
Abstract
INTRODUCTION: Little is known about the long-term health related quality of life outcomes in patients with West Nile virus associated acute flaccid paralysis. We describe the quality of life scores of seven patients with acute flaccid paralysis who presented to hospital between 2003 and 2006, and were followed for up to two years. CASE PRESENTATIONS: Between 2003 and 2006, 157 symptomatic patients with West Nile virus were enrolled in a longitudinal cohort study of West Nile virus in Canada. Seven patients (4%) had acute flaccid paralysis. The first patient was a 55-year-old man who presented with left upper extremity weakness. The second patient was a 54-year-old man who presented with bilateral upper extremity weakness. The third patient was a 66-year-old woman who developed bilateral upper and lower extremity weakness. The fourth patient was a 67-year-old man who presented with right lower extremity weakness. The fifth patient was a 60-year-old woman who developed bilateral lower extremity weakness. The sixth patient was a 71-year-old man with a history of Parkinson's disease and acute onset bilateral lower extremity weakness. The seventh patient was a 52-year-old man who presented with right lower extremity weakness. All were Caucasian. Patients were followed for a mean of 1.1 years. At the end of follow-up the mean score on the Physical Component Summary of the Short-Form 36 scale had only slightly increased to 39. In contrast, mean score on the Mental Component Summary of the Short-Form 36 scale at the end of follow-up had normalized to 50.Entities:
Year: 2011 PMID: 21854567 PMCID: PMC3177918 DOI: 10.1186/1752-1947-5-395
Source DB: PubMed Journal: J Med Case Rep ISSN: 1752-1947
Presenting clinical features of 7 cases of acute flaccid paralysis
| Baseline characteristics | Presenting clinical features | Therapeutic interventions | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 55y | M | None | No | LUE | No | - | - | Yes | No | No |
| 2 | 54y | M | Hypertension Dyslipidemia | No | Bilateral UE | No | <5 | <0.45 | No | No | No |
| 3 | 66y | F | None | No | Bilateral UE and LE | Yes | 123 | 1.27 | Yes | Yes | No |
| 4 | 67y | M | None | No | RLE | No | 189 | 1.04 | Yes | No | No |
| 5 | 60y | F | None | No | Bilateral LE | No | 32 | 0.77 | Yes | No | Yes (citalopram) |
| 6 | 71y | M | Heart failure Parkinson's | Yes | Bilateral LE | No | <5 | 1.06 | Yes | Yes | No |
| 7 | 52y | M | None | No | RLE | No | 39 | 1.35 | Yes | No | No |
Abbreviations: y, year; M, male; F, female; L, left; R, right; UE, upper extremity; LE, lower extremity; CSF, cerebrospinal fluid; WBC, white blood cell count; PT, physiotherapy; OT, occupational therapy.
PCS and MCS outcomes
| Case | PCS Scores | MCS Score | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31 | 34 | 59 | - | - | 28 | 30 | 55 | 62 | - | - | 32 | |
| 18 | 58 | 55 | 59 | 49 | 31 | 43 | 58 | 58 | 57 | 56 | 13 | |
| - | - | - | 28 | - | - | - | - | - | 33 | - | - | |
| 45 | 29 | 41 | 42 | - | -3 | 43 | 49 | 62 | 63 | - | 20 | |
| 29 | 38 | 37 | - | - | 8 | 33 | 39 | 34 | - | - | 1 | |
| 57 | 39 | 28 | 24 | 24 | -33 | 12 | 22 | 37 | 53 | 50 | 38 | |
| 26 | 32 | 36 | - | - | 10 | 41 | 55 | 54 | - | - | 13 | |
*The first three measurements were not obtained as the patient was ventilated and sedated in ICU.
†Score at the end of follow-up minus the score at baseline.